Instil Bio(TIL) - 2023 Q4 - Annual Results

Research and development expenses were $2.0 million and$39.6 million for the fourth quarter and full year ended December 31, 2023, respectively, compared to $20.7 million and$141.1 million for the fourth quarter and full year ended December 31, 2022, respectively. Instil Bio Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update DALLAS, TX, March 21, 2024 (GLOBE NEWSWIRE) Instil Bio, Inc. ("Instil") (NASDAQ: TIL), a clinical-stage biopharmaceutical company focused on dev ...